All In Biotech

Drug Trial Radar · NCT05745064

A Study of TL-925 as a Treatment for Dry Eye Disease

A Phase 2, Multicenter, Randomized, Double-masked, Placebo-controlled Study to Evaluate the Safety and Tolerability of TL-925 Ophthalmic Emulsion 0.1% in Subjects With Moderate to Severe Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Nov 18, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 107 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

107

Actual

Start

Feb 27, 2023

Primary completion

Jul 11, 2023

Study completion Jul 11, 2023

Sponsor

Lead sponsor
Telios Pharma, Inc.Industry
Sponsor type
Industry
First posted
Feb 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this prospective, Phase 2, multicenter, randomized, double-masked, placebo-controlled, parallel-arm study, approximately 100 subjects with moderate to severe dry eye disease (DED) will be randomly assigned (1:1) to receive either TL-925 or placebo as topical ophthalmic eye drops administered bilaterally BID. The study will comprise two phases: 2-weeks screening/run-in and 4-weeks double-masked treatment.

Conditions

  • Dry Eye Disease

Interventions

  • TL-925Drug

    TL-925 is an eye drop.

  • PlaceboDrug

    The composition of the placebo is identical to the active formulation except for the exclusion of the active ingredient.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Adverse events during screening & treatment periodTime frame: Baseline to the end of day 29 (±2 days)

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • Aesthetic Eye Care

    Newport Beach, California

  • Vision Institute

    Colorado Springs, Colorado

  • Michael Washburn Center for Ophthalmic Research, LLC.

    Indianapolis, Indiana

  • Andover Eye Associates

    Andover, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.